For UK healthcare professionals only. This promotional virtual meeting has been funded and organised by Alnylam UK Limited.

Click on the link below to access the prescribing information for AMVUTTRA®▼(vutrisiran).
Adverse Event Reporting can be found at the bottom of the page.

AMVUTTRA® Prescribing Information (UK)

ACT ON ATTR-CM: EVOLVING TREATMENT EXPECTATIONS IN SCOTLAND​

Friday 27th November 2026, 12:30 - 13:15 GMT | To be held virtually

For UK healthcare professionals only. This promotional virtual meeting has been funded and organised by Alnylam UK Limited.

Please note that some of the sessions will include data specific to products from Alnylam UK Limited.
‍
AMVUTTRA® is indicated for the treatment of wild-type or hereditary transthyretin amyloidosis in adult patients and cardiomyopathy (ATTR-CM).1
‍
AMVUTTRA® is indicated for the treatment of hereditary transthyretin-mediated amyloidosis (hATTR amyloidosis) in adult patients with stage 1 or stage 2 polyneuropathy.1

AMVUTTRA® is recommended by NICE as an option for the treatment of transthyretin amyloidosis in adults with cardiomyopathy (TA1115).2

AMVUTTRA® is recommended by NICE as an option for the treatment of hATTR in adults with stages 1 or 2 PN (TA868).3

Following an abbreviated submission, AMVUTTRA® is accepted for use within NHS Scotland for the treatment of hereditary transthyretin-mediated amyloidosis (hATTR amyloidosis) in adult patients with stage 1 or stage 2 polyneuropathy.4

Following a full submission, AMVUTTRA® is accepted for use within NHS Scotland for the treatment of wild-type or hereditary transthyretin amyloidosis in adult patients with cardiomyopathy (ATTR-CM). AMVUTTRA® is restricted for use as monotherapy for the treatment of adult patients with wild-type or hereditary ATTR-CM.5

ACT ON ATTR-CM: EVOLVING TREATMENT EXPECTATIONS IN SCOTLAND‍

Friday 27th November 2026, 12:30 - 13:15 GMT
‍

Speakers
Dr Joanne Simpson​
Consultant Cardiologist, NHS Greater Glasgow and Clyde, Queen Elizabeth University Hospital, and Honorary Senior Lecturer University of Glasgow​
‍
‍Dr William Moody
Consultant Cardiologist, Midlands Amyloidosis Service (MAS), University Hospitals Birmingham NHS Foundation Trust

‍Agenda
12:30–12:35 – Welcome and introduction (Dr Joanne Simpson)
12:35–12:45 – First-line treatment in ATTR-CM: redefining expectations with AMVUTTRA® (Dr William Moody)
12:45–13:00 – Suspect, screen, start: the pathway to early diagnosis and treatment in Scotland (Dr Joanne Simpson)
13:00–13:15 – Q&A (Dr Joanne Simpson and Dr William Moody)

Register for this event below:

REGISTER

If you have already registered, please join below:

JOIN

Stay in touch with Alnylam

CLICK HERE TO STAY IN TOUCH WITH ALNYLAM

To report an adverse event in the UK:

Adverse events should be reported. Reporting forms and information can be found at https://yellowcard/mhra.gov.uk/ or via the Yellow Card app available from the Apple App Store or Google Play Store. Adverse events should also be reported to Alnylam Pharmaceuticals at 0800 141 2569 (+44 1628 878 592) or medinfo@alnylam.com

Abbreviations
‍ATTR-CM, transthyretin amyloidosis with cardiomyopathy; hATTR, hereditary transthyretin amyloidosis; hATTR-PN, hereditary transthyretin amyloidosis with polyneuropathy; NHS, National Health Service; NICE, National Institute for Health and Care Excellence; PN, polyneuropathy; SMC, Scottish Medicines Consortium.

References
1. AMVUTTRA® Summary of Product Characteristics [accessed October 2026]; 2. National Institute for Health and Care Excellence. Vutrisiran for treating transthyretin amyloidosis with cardiomyopathy [TA1115]. Available at: https://www.nice.org.uk/guidance/ta1115 [accessed October 2026]; 3. National Institute for Health and Care Excellence. Vutrisiran for treating hereditary transthyretin-related amyloidosis [TA868]. Available at: https://www.nice.org.uk/guidance/ta868 [accessed October 2026]; 4. SMC. Vutrisiran 25 mg solution for injection in prefilled syringe (Amvuttra®). Available at: https://scottishmedicines.org.uk/medicines-advice/vutrisiran-amvuttra-abb-smc2596 [accessed October 2026]; 5. SMC. Vutrisiran sodium solution for injection in prefilled syringe (Amvuttra®). Available at: https://scottishmedicines.org.uk/medicines-advice/vutrisiran-amvuttra-full-smc2900 [accessed October 2026].

For UK healthcare professionals only.
This promotional virtual meeting has been funded and organised by Alnylam UK Limited.
© 2026 Alnylam Pharmaceuticals, Inc. All rights reserved.
AMV-UK-00754 | October 2026